Groundbreaking Gene Therapy Restores Vision in Retinitis Pigmentosa Patient

Strategic Insights -

At 61, a retinitis pigmentosa patient surnamed Zhao has regained her independence after losing her vision, thanks to a revolutionary gene therapy injection that restored her ability to cook, clean, and walk with ease. The breakthrough discovery of a unique photosensitive protein derived from chickens, known as opsin 5 (cOpn5), has enabled the development of an injectable solution using recombinant adeno-associated virus (AAV) to carry the gene encoding this light-sensitive protein. This has led to the creation of the gene therapy drug GA001, which has shown remarkable results in restoring vision in patients with retinitis pigmentosa.

Key Takeaways:

  • A team led by Prof. Luo Minmin at the Chinese Institute for Brain Research discovered the remarkable potential of opsin 5 (cOpn5), a unique photosensitive protein derived from chickens.
  • The protein exhibited exceptional sensitivity to visible light, especially within the blue-green spectrum, and was used to develop the injectable gene therapy drug GA001.
  • GA001 was effective in restoring vision in patients with retinitis pigmentosa, with a volunteer patient regaining enough vision to live independently within three to six months after treatment.
  • The treatment involves a simple and straightforward process, where a fine needle is used to inject the drug into the eye's vitreous cavity, requiring no invasive surgery or implanted devices.
  • GA001 stands out as a broad-spectrum therapy effective across various mutations and even for patients in late stages of the disease.
  • The success of GA001 has been recognized as one of the 10 major scientific and technological achievements in 2024 at the 2025 Zhongguancun Forum Annual Conference.
  • The drug is expected to progress to Phase I/II clinical trials by the end of 2025 and has the potential to serve as a first-in-class therapy for retinitis pigmentosa.
  • According to the China Association of Persons with Visual Disabilities, over 17 million people in China are visually impaired.
  • The need for elderly care among blind individuals is becoming increasingly urgent, and innovative therapies like GA001 have the potential to address this issue.

Statistics:

  • 1 in 4,000 people are affected by retinitis pigmentosa, indicating a significant market demand for GA001.
  • The number of visually impaired individuals in China is over 17 million.
  • Phase I/II clinical trials for GA001 are expected to begin by the end of 2025.
  • GA001 stands out as a broad-spectrum therapy effective across various mutations, providing a safer and more convenient treatment option for patients with retinitis pigmentosa.

Sources:

  • Xinhua via COMTEX
  • Chinese Institute for Brain Research
  • GenAns Biotech
  • Beijing Tiantan Hospital
  • China Association of Persons with Visual Disabilities
  • 2025 Zhongguancun Forum Annual Conference